TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20850004
Drug: Intravenous quinine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous quinine 20mg/kg initially then 10mg/kg three times a day
Study: 17550648
Drug: Diethylcarbamazine (DEC)
Normalized name: diethylcarbamazine
DrugBank: Diethylcarbamazine (DB00711)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diethylcarbamazine (DEC) alone (6 mg/kg)
Study: 17550648
Drug: Diethylcarbamazine (DEC)
Normalized name: diethylcarbamazine
DrugBank: Diethylcarbamazine (DB00711)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diethylcarbamazine (DEC) combined with Albendazole (ALB) (400 mg)
Study: 15370010
Drug: Naltrexone 50
Normalized name: naltrexone 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone 50 mg daily, with daily dispensing for the first 7 days and weekly dispensing for the following 11 weeks
Study: 11372045
Drug: PGV (cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGV (cisplatin 50 mg/m², gemcitabine 1000 mg/m², vinorelbine 25 mg/m²)
Study: 11372045
Drug: PGT (cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGT (cisplatin 50 mg/m², gemcitabine 1000 mg/m², paclitaxel 125 mg/m²)
Study: 11372045
Drug: PG (cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: PG (cisplatin 100 mg/m², gemcitabine 1000 mg/m²)
Study: 9215189
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg vaginal prostaglandin E2 gel
Study: 9215189
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg intracervical prostaglandin E2 gel
Study: 25500488
Drug: Liposomal curcumin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal curcumin (10 - 400 mg/m2)
Study: 25500488
Drug: Liposomal curcumin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal curcumin (≥ 120 mg/m2)
Study: 25500488
Drug: Liposomal curcumin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal curcumin (up to 120 mg/m2)
Study: 18514162
Drug: 0.67 mg/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.67 mg/L solution
Study: 18514162
Drug: 5.45 mg/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.45 mg/L solution
Study: 16817039
Drug: Cyclic etidronate
Normalized name: etidronate
DrugBank: Etidronic acid (DB01077)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cyclic etidronate therapy (oral regimen repeated every 14 weeks)
Study: 10618952
Drug: Saline dilution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline dilution (20% with 0.9% saline, 1 ml)
Study: 10618952
Drug: Aspirin (375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (375 mg daily for 3 days)
Study: 7488989
Drug: Palliative-treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palliative-treatment
Study: 1903558
Drug: misoprostol, 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: misoprostol, 400 micrograms twice daily
Study: 1903558
Drug: high‐dose liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: high‐dose liquid antacid regimen
Study: 27722224
Drug: Immediate post-extractive
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate post-extractive ultra-wide 7 mm-diameter implants (group A)
Study: 27722224
Drug: Delayed implant
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed implant installation 4 months after tooth extraction and socket preservation (group B)
Study: 20336635
Drug: Estrogen‐plus‐progestin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen‐plus‐progestin therapy (CHT)
Study: 16028129
Drug: Therapeutic vaccines
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic vaccines (ALVAC-HIV [vCP1452] or ALVAC-HIV and Remune)
Study: 11796648
Drug: Ranitidine (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (75 mg)
Study: 7749166
Drug: Navoban (tropisetron)
Normalized name: benzocaine / trimethobenzamide hydrochloride Rectal Suppository [Navogan]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Navoban (tropisetron) 5 mg once daily
Study: 7749166
Drug: Navoban (tropisetron)
Normalized name: benzocaine / trimethobenzamide hydrochloride Rectal Suppository [Navogan]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Navoban (tropisetron) 10 mg once daily
Study: 7749166
Drug: Dexamethasone (Day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (Day 1, 0.2 mg/kg i.v.; Days 2-6, 8 mg p.o.)
Study: 7749166
Drug: Alizapride (Day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alizapride (Day 1, 100 mg i.v. and 4 x 50 mg p.o.; Days 2-6, 4 x 5 mg p.o.)
Study: 30131296
Drug: Inhaled normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled normal saline (placebo)
Study: 27827358
Drug: Aromatase inhibitors
Normalized name: Aromatase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatase inhibitors (AIs) treatment
Study: 20146631
Drug: elvitegravir 50
Normalized name: Elvitegravir
DrugBank: Elvitegravir (DB09101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: elvitegravir 50 mg
Study: 20146631
Drug: elvitegravir 125
Normalized name: Elvitegravir
DrugBank: Elvitegravir (DB09101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: elvitegravir 125 mg
Study: 2246794
Drug: Cognitive Marital
Normalized name: barbital
DrugBank: Barbital (DB01483)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Marital Therapy
Study: 29127575
Drug: Bright white
Normalized name: PROPOLIS EXTRACT 7 g in 140 g / MENTHA PIPERITA (PEPPERMINT) STEM EXTRACT 1.4 g in 140 g / CHRYSANTHELLUM INDICUM FLOWER OIL 1.4 g in 140 g ORAL PASTE [BARUBT Probiotics Bright White Tooth-Paste]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bright white light (BWL) therapy for 30 minutes daily for 28 days
Study: 29127575
Drug: Dim red
Normalized name: acid red 35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dim red light (DRL) therapy for 30 minutes daily for 28 days
Study: 21332628
Drug: Ezetimibe 10
Normalized name: ezetimibe 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe 10 mg plus statin (EZE/statin)
Study: 18362594
Drug: Melatonin (3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (3.0 mg)
Study: 17174195
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg NM-702
Study: 17174195
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg NM-702
Study: 17174195
Drug: NM-702 (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: NM-702 (both doses)
Study: 14702886
Drug: Postpartum mood
Normalized name: BluesAway Postpartum Mood Support Liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postpartum mood disorder treatments (specific treatments not detailed in the abstract)
Study: 10879333
Drug: Substance abuse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Substance abuse treatment with prenatal care
Study: 9487448
Drug: Regimen I
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen I (2EHRZ7/6EH7): 8-month daily regimen of ethambutol, isoniazid, rifampicin, and pyrazinamide for 2 months, followed by ethambutol and isoniazid for 6 months.
Study: 9487448
Drug: Regimen II
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen II (2EHRZ2/4EHR2): 6-month twice-weekly regimen with the same four drugs for 2 months, followed by ethambutol, rifampicin, and isoniazid for 4 months.
Study: 8238493
Drug: High insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High insulin infusion (3,620 +/‐ 476 pM)
Study: 3552204
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of cyclophosphamide
Study: 3552204
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of cyclophosphamide
Study: 30312165
Drug: Herbal decoction
Normalized name: Hyperici herba
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal decoction (180 mL of Cassia fistula L pod's pericarp and Myristica fragrans Houtt arils)
Study: 30312165
Drug: Mefenamic acid
Normalized name: Mefenamic Acid
DrugBank: Mefenamic acid (DB00784)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mefenamic acid (500 mg orally twice daily)
Study: 12871321
Drug: Hormone therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone therapy (n = 357; opposed (n = 290) and unopposed (n = 67))
Study: 12871321
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (control group, n = 362)
Study: 10741256
Drug: Semax administered
Normalized name: semax
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semax administered intransally as nasal drops
Study: 10741256
Drug: Semax administered
Normalized name: semax
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semax administered by endonasal electrophoresis
Study: 6384851
Drug: Antifibrinolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antifibrinolytic therapy (tranexamic acid)
Study: 6384851
Drug: No antifibrinolytic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antifibrinolytic therapy (Control)
Study: 26980919
Drug: Flurbiprofen spray
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flurbiprofen spray (3 times daily)
Study: 26980919
Drug: Placebo solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution (3 times daily)
Study: 22902096
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (Simvastatin and Bezafibrate)
Study: 19953579
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg epinephrine plus normal saline (group 1; n = 38)
Study: 19953579
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg epinephrine plus 3% saline (group 2; n = 39)
Study: 19953579
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg salbutamol plus normal saline (group 3; n = 36)
Study: 19953579
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg salbutamol plus 3% saline (group 4; n = 36)
Study: 12585098
Drug: Conventional method
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional method with corticosteroids and/or immunosuppressant
Study: 1300803
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy and preoperative radiotherapy
Study: 3895037
Drug: Isoniazid therapy
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoniazid therapy (up to 1200 mg/d)
Study: 23512235
Drug: Intra-space injection
Normalized name: somatropin
DrugBank: Somatotropin (DB00052)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intra-space injection of Twin mix
Study: 23512235
Drug: Per-oral dexamethasone
Normalized name: dexamethasone Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Per-oral dexamethasone
Study: 19858140
Drug: L-FMC after
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-FMC after isometric exercise
Study: 19858140
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of L-FMC and FMD
Study: 17645472
Drug: peg‐IFN 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: peg‐IFN 1.0 mug/kg/week + ribavirin 10.6 mg/kg/day
Study: 17645472
Drug: peg‐IFN 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: peg‐IFN 1.5 microg/kg/week + ribavirin 10.6 mg/kg/day
Study: 15980699
Drug: VaxGen VAX004
Approvals — FDA: no, EMA: no, PMDA: no
Description: VaxGen VAX004 study (HIV vaccine efficacy trial)
Study: 2841251
Drug: Enalapril (20-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (20-40 mg)
Study: 2841251
Drug: Captopril (50-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (50-100 mg)
Study: 16284232
Drug: Eprosartan 600
Normalized name: eprosartan 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eprosartan 600 mg daily
Study: 10902987
Drug: Energy supplement
Normalized name: Nutritional Supplement Oral Bar [PROTEIN FORTIFIED ENERGY SUPPLEMENT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Energy supplement (1171 kJ + 12 mg iron)
Study: 10902987
Drug: Micronutrient supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronutrient supplement (209 kJ + 12 mg iron)
Study: 9166392
Drug: HRT +
Normalized name: Hormone Replacement Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRT + Vit D (2 mg estradiol valerate and 1 mg cyproterone acetate + 300 IU/day vitamin D3)
Study: 9166392
Drug: Placebo (calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (calcium lactate; 93 mg Ca2+/day)
Study: 8335785
Drug: Sealants applied
Normalized name: thrombin
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sealants applied with a bonding agent on wet enamel
Study: 8335785
Drug: Sealants applied
Normalized name: thrombin
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sealants applied without a bonding agent on wet enamel
Study: 26573925
Drug: liraglutide (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: liraglutide (0.6 mg for 2 days, 1.2 mg for 2 days, followed by 1.8 mg for 3 days)
Study: 22628062
Drug: Escitalopram formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram formulation by Grupo Tecnimede
Study: 22628062
Drug: European reference
Approvals — FDA: no, EMA: no, PMDA: no
Description: European reference formulation
Study: 16171242
Drug: Pregabalin 150
Normalized name: pregabalin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin 150 mg t.i.d.
Study: 16171242
Drug: Alprazolam 1
Normalized name: alprazolam 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam 1 mg t.i.d.
Study: 10227337
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP) 220 microg twice daily
Study: 1650315
Drug: Sulindac, 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulindac, 300 mg/day
Study: 7280947
Drug: No parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: No parenteral antibiotics
Study: 30616441
Drug: Stay Balanced
Normalized name: benzalkonium chloride Topical Foam [Stay Clean]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stay Balanced program (progressive balance training, group sessions twice a week for 10 weeks)
Study: 28359259
Drug: Sedative group
Normalized name: MedActive Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sedative group (Propofol and sufentanil)
Study: 28359259
Drug: Routine group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine group (without sedative)
Study: 18379759
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg oxycodone
Study: 10634646
Drug: G-CSF +
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF + HDMP
Study: 8729209
Drug: Rifabutin (450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifabutin (450 or 600 mg/d)
Study: 1420648
Drug: Naloxone infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone infusion (10 mg plus 7 mg/hr for a total of 94 mg)
Study: 3841228
Drug: Pirenzepine 40
Normalized name: pirenzepine
DrugBank: Pirenzepine (DB00670)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirenzepine 40 mg
Study: 21358504
Drug: 1.8 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.8 g/d N-3 (omega-3 fatty acids)
Study: 17008194
Drug: Naltrexone (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (25 mg daily for 3 days prior to quit date, then 50 mg/day for 8 weeks)
Study: 14676759
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg penicillin G potassium troches (Cankercillin)
Study: 10708160
Drug: Flumazenil (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil (0.5 mg bolus injection)
Study: 9089853
Drug: Caudal epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal epidural block with 0.6 mL/kg of 0.25% bupivacaine with 1:200,000 epinephrine before incision (n = 28)
Study: 9089853
Drug: Caudal epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal epidural block with 0.6 mL/kg of 0.25% bupivacaine with 1:200,000 epinephrine after surgery (n = 23)
Study: 24021667
Drug: Facial‐Oral Tract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Facial‐Oral Tract Therapy
Study: 20080201
Drug: Formoterol 12
Normalized name: formoterol 12 mcg inhalation capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formoterol 12 microg twice-daily
Study: 16793625
Drug: Delisheng injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delisheng injection combined with IMRT
Study: 15115135
Drug: Both vaccines
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both vaccines concomitantly
Study: 1595104
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 75 mg dipyridamole and 330 mg acetylsalicylic acid three times a day
Study: 6142906
Drug: Triazolam (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triazolam (0.5 mg) with ethanol (60 ml vodka + 60 ml water)
Study: 6142906
Drug: Triazolam (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triazolam (0.5 mg) with water (100 to 200 ml)
Study: 28670938
Drug: Aspirin 75
Normalized name: aspirin 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 75 mg daily for four weeks
Study: 27038034
Drug: High-dose glucocorticosteroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose glucocorticosteroid treatment
Study: 27038034
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose glucocorticosteroid treatment
Study: 27038034
Drug: Another type
Normalized name: collagen type I
Approvals — FDA: no, EMA: no, PMDA: no
Description: Another type of high-dose glucocorticosteroid treatment
Study: 25381721
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg ETV once daily; 2 g RGT three times daily
Study: 25381721
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg ETV once daily; 2 g RGT dummy agent three times daily
Study: 16040370
Drug: Single drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single drug alcohol intervention
Study: 11989836
Drug: Wheat grass
Normalized name: Wheat grass
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wheat grass juice (100 cc daily for 1 month)
Study: 10084293
Drug: Intravenous L-carnitine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous L-carnitine (5 mg/kg for 15 patients and 25 mg/kg for 5 patients) with intravenous iron saccharate (20 mg/HD session) for four months.
Study: 10084293
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with intravenous iron saccharate (20 mg/HD session) for four months.
Study: 10084293
Drug: Intravenous L-carnitine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous L-carnitine with iron supplementation.
Study: 2127377
Drug: Sublingual nitroglycerin
Normalized name: nitroglycerin Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual nitroglycerin spray (0.4 mg)
Study: 2127377
Drug: Sublingual nitroglycerin
Normalized name: nitroglycerin Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual nitroglycerin tablet (0.4 mg)
Study: 26372387
Drug: Darunavir/ritonavir monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darunavir/ritonavir monotherapy (DRV/r) 800/100 mg once daily
Study: 26372387
Drug: Darunavir/ritonavir with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darunavir/ritonavir with two nucleoside analogues (triple therapy)
Study: 24231879
Drug: Top-dose phentermine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Top-dose phentermine plus topiramate-extended release (15/92 mg)
Study: 21932023
Drug: Immediate placement
Normalized name: IR DIP 10 1 % Iodine Replacement Teat Dip
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate placement of OsseoSpeed implants in fresh extraction sockets
Study: 21932023
Drug: Immediate placement
Normalized name: IR DIP 10 1 % Iodine Replacement Teat Dip
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate placement of OsseoSpeed implants in healed edentulous ridges
Study: 17530036
Drug: Cefditoren pivoxil
Normalized name: Cefditoren Pivoxil
DrugBank: Cefditoren (DB01066)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefditoren pivoxil 200 mg single dose
Study: 17530036
Drug: Cefditoren pivoxil
Normalized name: Cefditoren Pivoxil
DrugBank: Cefditoren (DB01066)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefditoren pivoxil 400 mg single dose
Study: 17530036
Drug: Cefditoren pivoxil
Normalized name: Cefditoren Pivoxil
DrugBank: Cefditoren (DB01066)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefditoren pivoxil 400 mg b.i.d. for 10 days
Study: 17530036
Drug: Cefditoren pivoxil
Normalized name: Cefditoren Pivoxil
DrugBank: Cefditoren (DB01066)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefditoren pivoxil 400 mg t.i.d. for 10 days
Study: 17530036
Drug: Cefditoren pivoxil
Normalized name: Cefditoren Pivoxil
DrugBank: Cefditoren (DB01066)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefditoren pivoxil 400 mg b.i.d. and t.i.d.
Study: 17530036
Drug: Cefditoren pivoxil
Normalized name: Cefditoren Pivoxil
DrugBank: Cefditoren (DB01066)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefditoren pivoxil 400 mg t.i.d.
Study: 11704172
Drug: ORTHO EVRA/EVRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: ORTHO EVRA/EVRA (transdermal contraceptive system delivering norelgestromin 150 microg and ethinyl estradiol 20 microg daily)
Study: 9600581
Drug: Buspirone (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone (3 x 5 mg)
Study: 9600581
Drug: Lorazepam (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam (3 x 1 mg)
Study: 31506077
Drug: 12-week dietary
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12-week dietary intervention promoting weekly consumption of 2.5 cups of cruciferous vegetables and 3.5 cups of green leafy vegetables
Study: 23130655
Drug: SRP plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRP plus 1% metformin gel
Study: 15084614
Drug: ATRA and
Normalized name: ATRA
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ATRA and chemotherapy (CT) for maintenance
Study: 11437888
Drug: Aspirin (320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (320 mg administered three times at 4-hour intervals)
Study: 7935224
Drug: GTN (0.1%,
Approvals — FDA: no, EMA: no, PMDA: no
Description: GTN (0.1%, solved in NaCl; dose 2.8 +/- 0.5 mg/h)